"Medical Journeys" chart a path each step of the way for physicians ... anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi). It became the first in the class to move from ...

The Freshwater Ecosystems Explorer offers what experts call an unprecedented look at the world’s lakes, rivers and wetlands, ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at up-to-date safety data on Leqembi (lecanemab) at its next meeting in ...

A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

The accelerated approval is based on phase 2 data demonstrating that Leqembi reduced the accumulation of amyloid in the brain, although interim results from the phase 3 CLARITY-AD study revealed a ...

The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year ... were primarily based on phase 3 data from Eisai’s global Clarity AD clinical trial, in which it met its ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...

More than just a compilation of data, it spotlights the changes in the music industry's dynamics and trends. The chart is announced every Tuesday. The chart was launched by the International ...